Stock IKT INHIBIKASE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-20 EDT 		5-day change 1st Jan Change
1.86 USD +7.51% Intraday chart for Inhibikase Therapeutics, Inc. +36.76% +46.46%
05-16 Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024
05-09 Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension CI

Business Summary

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.

Number of employees: 9

Sales per Business

USD in Million2022Weight2023Weight Delta
Protein Kinase Inhibitor Therapeutics
100.0 %
0 100.0 % 0 100.0 % +111.03%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 0 100.0 % +111.03%

Managers

Managers TitleAgeSince
Milton Werner FOU
 Founder 61 08-08-31
C. Warren Olanow CTO
 Chief Tech/Sci/R&D Officer - 21-01-03
Surendra Singh COO
 Chief Operating Officer - 14-03-31
Dan Williams AUD
 Comptroller/Controller/Auditor - -
W. Roger Rush PRN
 Corporate Officer/Principal - 14-12-31
Merrill M. Kraines LAW
 General Counsel - -

Members of the board

Members of the board TitleAgeSince
Dennis Berman BRD
 Director/Board Member 73 19-08-31
Paul Grint BRD
 Director/Board Member 66 20-12-21
Milton Werner FOU
 Founder 61 08-08-31
Gisele Dion BRD
 Director/Board Member 57 22-08-31
Roy Freeman BRD
 Director/Board Member 72 20-12-21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 6,476,844 5,579,587 ( 86.15 %) 0 86.15 %

Shareholders

NameEquities%Valuation
Milton Werner
13.73 %
889,242 13.73 % 2 M $
FiveT Capital AG
3.451 %
223,500 3.451 % 424 650 $
William Blair & Co. LLC
1.183 %
76,601 1.183 % 145 542 $
Geode Capital Management LLC
0.4430 %
28,692 0.4430 % 54 515 $
G1 Execution Services LLC
0.3492 %
22,616 0.3492 % 42 970 $
Renaissance Technologies LLC
0.3307 %
21,422 0.3307 % 40 702 $
Redmond Asset Management LLC
0.3020 %
19,560 0.3020 % 37 164 $
Vanguard Group, Inc. (Subfiler)
0.2582 %
16,724 0.2582 % 31 776 $
STATE STREET CORPORATION
0.1557 %
10,084 0.1557 % 19 160 $
Joseph Frattaroli
0.1237 %
8,015 0.1237 % 15 229 $

Company contact information

Inhibikase Therapeutics, Inc.

3350 Riverwood Parkway South East Suite 1900

30339, Atlanta

+678 392 3419

http://www.inhibikase.com
address Inhibikase Therapeutics, Inc.(IKT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.73 USD
Average target price
17.5 USD
Spread / Average Target
+911.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
INHIBIKASE THERAPEUTICS, INC. Stock Inhibikase Therapeutics, Inc.
+46.46% 11.2M
MODERNA, INC. Stock Moderna, Inc.
+41.79% 50.93B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.56% 42.12B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.05B
CELLTRION, INC. Stock Celltrion, Inc.
-7.20% 29.18B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.59% 26.02B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.51% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+6.92% 13.21B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.91% 12.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.60% 12.16B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IKT Stock
  4. Company Inhibikase Therapeutics, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW